cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease.

[1]  S. Mandel,et al.  The Pivotal Role of Iron in NF‐κB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators , 1999, Annals of the New York Academy of Sciences.

[2]  S. Mandel,et al.  Apomorphine protects against MPTP‐induced neurotoxicity in mice , 1999, Movement disorders : official journal of the Movement Disorder Society.

[3]  R. Djaldetti,et al.  IL-1β, IL-2, IL-6 and TNF-α production by peripheral blood mononuclear cells from patients with Parkinson's disease , 1999 .

[4]  S. Gullans,et al.  Characterization of the Hsp110/SSE gene family response to hyperosmolality and other stresses. , 1998, American journal of physiology. Renal physiology.

[5]  M. Youdim,et al.  Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6‐Hydroxydopamine , 1998, Movement disorders : official journal of the Movement Disorder Society.

[6]  Y Agid,et al.  Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Brittenham,et al.  Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. , 1997, The American journal of physiology.

[8]  C. Olanow,et al.  Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.

[9]  T. Nagatsu,et al.  Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.

[10]  P. Riederer,et al.  Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? , 1994, Journal of neurochemistry.

[11]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[12]  P. Baeuerle,et al.  Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF‐kappa B transcription factor and HIV‐1. , 1991, The EMBO journal.

[13]  N. Neff,et al.  Epidermal Growth Factor Enhances Striatal Dopaminergic Parameters in the 1‐Methyl‐4‐Phenyl‐l, 2, 3, 6‐Tetrahydropyridine‐Treated Mouse , 1991, Journal of neurochemistry.

[14]  J. Cadet,et al.  Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence , 1989, Brain Research.

[15]  P. Goodfellow,et al.  DNA microarrays in drug discovery and development , 1999, Nature Genetics.

[16]  P. Riederer,et al.  The possible role of iron in the etiopathology of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[17]  K. Jellinger,et al.  Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.